{
  "schemaVersion": "2.0",
  "lastUpdated": "2025-01-09",
  
  "substances": [
    {
      "id": "2cb_001",
      "name": "2C-B",
      "aliases": ["4-bromo-2,5-dimethoxyphenethylamine", "Nexus", "Venus"],
      "classification": {
        "primary": "non-classical_serotonergic_psychedelic",
        "secondary": ["phenethylamine", "substituted_phenethylamine"],
        "mechanism": "5-HT2A_partial_agonist",
        "receptorAffinity": {
          "5HT2A": "low_to_moderate",
          "5HT2C": "moderate",
          "note": "Lower or negligible activity at 5-HT2A compared to classical psychedelics"
        }
      },
      "synthesisHistory": {
        "creator": "Alexander Shulgin",
        "year": 1970,
        "context": "Synthesized as part of systematic exploration of phenethylamine derivatives"
      },
      "prevalenceData": {
        "marketPresence": {
          "availability": "Illicit drug market",
          "formulations": ["tablets", "powder", "crystal"],
          "falsificationRate": "low",
          "context": "Often found in combination with MDMA",
          "citations": ["caudevilla_2012", "palamar_2020"]
        },
        "coUsePatterns": {
          "primaryCoSubstance": "MDMA",
          "coUseRate": "high",
          "context": "2023 global survey showed high rate of co-use among 11 psychedelic substances",
          "citations": ["caudevilla_2012"]
        }
      },
      "dosing": {
        "threshold": {"value": 1, "unit": "mg"},
        "light": {"min": 1, "max": 5, "unit": "mg", "notes": "Subtle perceptual and emotional effects"},
        "common": {"min": 10, "max": 25, "unit": "mg", "notes": "Typical recreational range"},
        "strong": {"min": 20, "max": 30, "unit": "mg", "notes": "Intense psychedelic experiences"},
        "heavy": {"min": 30, "unit": "mg", "notes": "Very intense, increased risk"},
        "therapeutic": {
          "status": "not_established",
          "notes": "No established therapeutic protocols or dosing guidelines"
        },
        "weightDependence": "unknown",
        "notes": "Difficult to achieve consistent dosing due to illicit market variability"
      },
      "pharmacokinetics": {
        "absorption": {
          "route": "oral_primary",
          "alternativeRoutes": ["insufflation", "rectal"],
          "insufflationRisks": "Severe neurological reactions including central serotonin syndrome, epileptic seizures, cerebral edema, cerebral vasculopathy"
        },
        "onset": {"min": 20, "max": 60, "unit": "minutes"},
        "peak": {"min": 60, "max": 120, "unit": "minutes"},
        "duration": {"min": 6, "max": 8, "unit": "hours"},
        "metabolism": "Unknown specific pathways",
        "elimination": "Unknown"
      },
      "subjectiveEffectTimeline": {
        "acute": {
          "timeframe": "0-240 minutes",
          "predominantEffects": [
            "visual_distortions",
            "enhanced_sensory_perception",
            "emotional_shifts",
            "euphoria",
            "altered_thought_processes"
          ],
          "comparison": "Often described as 'lighter' or more manageable than LSD"
        },
        "similarities": {
          "ayahuasca": "Similar enhanced sensory perception",
          "salvia": "Similar perceptual quality"
        }
      },
      "toleranceDevelopment": {
        "rate": "presumed_rapid",
        "crossTolerance": ["LSD", "mescaline", "other_phenethylamines"],
        "duration": "unknown",
        "notes": "Limited research data available"
      },
      "addictionPotential": "minimal_to_unknown",
      "physiologicalDependence": "none reported",
      "psychologicalDependence": "rare"
    },
    {
      "id": "2ci_001",
      "name": "2C-I",
      "aliases": ["4-iodo-2,5-dimethoxyphenethylamine"],
      "classification": {
        "primary": "non-classical_serotonergic_psychedelic",
        "secondary": ["phenethylamine", "substituted_phenethylamine"],
        "mechanism": "5-HT2A_partial_agonist"
      },
      "knownRisks": {
        "psychological": [
          "paranoid_ideation",
          "aggression",
          "confusion"
        ],
        "physiological": [
          "tachycardia",
          "hypertension",
          "renal_failure",
          "seizures",
          "cardiac_arrest",
          "respiratory_arrest"
        ],
        "citations": ["baumeister_2015"]
      },
      "dosing": {
        "notes": "Limited reliable dosing information available; high risk compound"
      }
    },
    {
      "id": "25i_nbome_001",
      "name": "25I-NBOMe",
      "aliases": ["2C-I-NBOMe"],
      "classification": {
        "primary": "novel_psychedelic_substance",
        "secondary": ["phenethylamine", "substituted_phenethylamine", "NBOMe_series"],
        "mechanism": "5-HT2A_full_agonist",
        "note": "Significantly more potent and dangerous than classical psychedelics"
      },
      "prevalenceData": {
        "adulterationRisk": {
          "soldAs": ["LSD", "MDMA"],
          "prevalence": "common",
          "riskLevel": "high",
          "citations": ["hirschfeld_2021", "malcolm_2022"]
        }
      },
      "hppdRisk": {
        "regularUse": {
          "value": 67,
          "unit": "percent",
          "context": "Chronic or prolonged effects with regular use"
        },
        "singleUse": {
          "value": 20,
          "unit": "percent",
          "context": "Risk even from single use"
        },
        "citations": ["retrospective_analysis_nd"]
      },
      "knownRisks": {
        "toxicity": "higher_than_classical_psychedelics",
        "unpredictableEffects": true,
        "prolongedEffects": true,
        "severeAdverseReactions": "documented",
        "fatalities": "documented"
      }
    }
  ],

  "setFactors": [
    {
      "id": "set_expectations_001",
      "name": "Expectations and Intentions",
      "category": "cognitive",
      "description": "Individual's mindset, goals, and expectations entering experience",
      "components": [
        {
          "name": "Intentions",
          "importance": "high",
          "effect": "Clear intentions associated with better outcomes",
          "riskOfAbsence": "Confusion, disorientation, difficulty integrating",
          "specificTo2CX": "Limited therapeutic research means fewer established frameworks for intention-setting"
        },
        {
          "name": "Expectations",
          "importance": "high",
          "effect": "Unrealistic expectations can lead to disappointment or distress",
          "specificTo2CX": "Often described as 'lighter' than other psychedelics, which may lead to underestimation of intensity",
          "mediatingFactors": ["media_portrayal", "peer_reports", "preparation_quality"]
        }
      ],
      "modifiability": "high"
    },
    {
      "id": "set_personality_001",
      "name": "Personality Traits",
      "category": "trait",
      "traits": [
        {
          "trait": "Neuroticism",
          "effect": "negative",
          "strength": "strong_predictor",
          "specificRisks": ["anxiety", "panic", "paranoia"]
        },
        {
          "trait": "Openness to Experience",
          "effect": "positive",
          "strength": "moderate_predictor",
          "specificBenefits": ["better_navigation_of_novel_states"]
        },
        {
          "trait": "Suggestibility",
          "effect": "risk_factor",
          "specificRisks": ["susceptible_to_influence", "belief_manipulation"]
        }
      ],
      "modifiability": "low"
    }
  ],

  "riskFactors": [
    {
      "id": "rf_cardiovascular_001",
      "name": "Pre-existing cardiovascular conditions",
      "category": "physiological",
      "subcategory": "cardiovascular",
      "description": "Heart conditions, hypertension, arrhythmias",
      "severity": "high",
      "substanceInteractions": [
        {
          "substanceId": "2cb_001",
          "mechanism": "Increases blood pressure, heart rate, and body temperature",
          "riskLevel": "moderate_to_high",
          "specificConditions": [
            {
              "condition": "uncontrolled_hypertension",
              "contraindicationType": "absolute",
              "severity": "critical"
            },
            {
              "condition": "arrhythmias",
              "contraindicationType": "absolute",
              "severity": "critical"
            },
            {
              "condition": "coronary_artery_disease",
              "contraindicationType": "relative",
              "requiresMonitoring": true,
              "severity": "high"
            }
          ],
          "citations": ["aday_2020", "fonzo_2025"],
          "evidenceQuality": "low_extrapolated_from_other_psychedelics"
        },
        {
          "substanceId": "2ci_001",
          "mechanism": "Documented tachycardia and hypertension",
          "riskLevel": "high",
          "specificRisks": [
            "tachycardia",
            "hypertension",
            "cardiac_arrest"
          ],
          "citations": ["baumeister_2015"],
          "evidenceQuality": "moderate"
        }
      ],
      "monitoringRecommendations": [
        "Baseline ECG",
        "Continuous vital sign monitoring during session",
        "Medical supervision required"
      ]
    },
    {
      "id": "rf_serotonergic_medication_001",
      "name": "Concurrent Serotonergic Medications",
      "category": "pharmacological",
      "subcategory": "drug_interactions",
      "description": "Use of medications affecting serotonin levels",
      "severity": "critical",
      "substanceInteractions": [
        {
          "substanceId": "2cb_001",
          "medications": ["SSRIs", "MAOIs", "triptans"],
          "mechanism": "Increased risk of serotonin toxicity/syndrome",
          "riskLevel": "high",
          "contraindicationType": "absolute",
          "specificRisks": [
            "serotonin_syndrome",
            "hyperthermia",
            "seizures",
            "death"
          ],
          "citations": ["hirschfeld_2021"],
          "evidenceQuality": "moderate"
        }
      ],
      "prevention": [
        "Comprehensive medication review",
        "Discontinuation of serotonergic medications with appropriate washout period",
        "Education about dangerous combinations"
      ]
    },
    {
      "id": "rf_polydrug_use_001",
      "name": "Concurrent Polydrug Use",
      "category": "behavioral",
      "subcategory": "substance_use",
      "description": "Use of multiple substances simultaneously or in close temporal proximity",
      "severity": "high",
      "prevalenceData": {
        "coUseWithMDMA": {
          "prevalence": "high",
          "context": "2C-B frequently combined with MDMA",
          "citations": ["caudevilla_2012"]
        }
      },
      "substanceInteractions": [
        {
          "substanceId": "2cb_001",
          "commonCombinations": [
            {
              "substances": ["2C-B", "MDMA"],
              "effect": "Unpredictable interactions, increased physiological burden",
              "prevalence": "very_common"
            },
            {
              "substances": ["2C-B", "alcohol"],
              "effect": "Increased adverse effects"
            },
            {
              "substances": ["2C-B", "cannabis"],
              "effect": "Variable - may reduce or exacerbate difficulty"
            }
          ],
          "citations": ["kopra_2025", "breeksema_2022"]
        }
      ],
      "harmReductionStrategies": [
        "Substance testing",
        "Avoiding combinations",
        "Education about dangerous interactions",
        "Starting with single substances"
      ]
    },
    {
      "id": "rf_age_youth_001",
      "name": "Adolescence and Young Adulthood",
      "category": "demographic",
      "subcategory": "age",
      "ageRange": {"min": 13, "max": 25},
      "description": "Younger age associated with increased vulnerability",
      "severity": "moderate_to_high",
      "substanceInteractions": [
        {
          "substanceId": "*",
          "mechanism": "Developing brain more susceptible to disruption",
          "riskLevel": "elevated",
          "specificRisks": [
            "negative_psychological_effects",
            "higher_emergency_treatment_rates",
            "potential_developmental_disruption"
          ],
          "prevalenceData": {
            "negativeEffects": {
              "value": 53,
              "unit": "percent",
              "context": "Of those with negative effects were under 25",
              "citation": "bremler_2023"
            }
          }
        }
      ]
    },
    {
      "id": "rf_route_insufflation_001",
      "name": "Insufflation Route of Administration",
      "category": "behavioral",
      "subcategory": "administration_route",
      "description": "Intranasal administration of 2C-B",
      "severity": "critical",
      "specificTo2CX": true,
      "substanceInteractions": [
        {
          "substanceId": "2cb_001",
          "route": "insufflation",
          "specificRisks": [
            "severe_neurological_reactions",
            "central_serotonin_syndrome",
            "epileptic_seizures",
            "cerebral_edema",
            "cerebral_vasculopathy"
          ],
          "riskLevel": "critical",
          "citations": ["hirschfeld_2021"],
          "evidenceQuality": "moderate"
        }
      ],
      "prevention": [
        "Strong warnings against insufflation",
        "Education about oral administration as safer route",
        "Clear communication about severe neurological risks"
      ]
    },
    {
      "id": "rf_lithium_interaction_001",
      "name": "Lithium Co-Administration",
      "category": "pharmacological",
      "subcategory": "drug_interactions",
      "description": "Concurrent use with lithium medication",
      "severity": "critical",
      "substanceInteractions": [
        {
          "substanceId": "*",
          "medication": "lithium",
          "mechanism": "Significantly increased risk of seizures",
          "riskLevel": "critical",
          "contraindicationType": "absolute",
          "specificRisks": ["seizures"],
          "citations": ["nayak_2021"],
          "evidenceQuality": "strong"
        }
      ]
    },
    {
      "id": "rf_inadequate_harm_reduction_info_001",
      "name": "Lack of Harm Reduction Information",
      "category": "educational",
      "subcategory": "information_access",
      "description": "Limited access to accurate, evidence-based information",
      "severity": "moderate_to_high",
      "specificTo2CX": "Very limited research means less reliable information available",
      "consequences": [
        "Inadequate preparation",
        "Insufficient knowledge about interactions",
        "Inability to recognize early warning signs",
        "Poor dosing decisions",
        "Increased risk of adverse events"
      ],
      "citations": ["breeksema_2022", "kopra_2022", "pleet_2023"],
      "interventions": [
        "Comprehensive public education",
        "Peer support networks",
        "Online harm reduction resources",
        "Professional consultation access"
      ]
    }
  ],

  "medicalConditions": [
    {
      "id": "cond_psychotic_disorders_001",
      "name": "Psychotic Disorders",
      "category": "psychiatric",
      "icd10": "F20-F29",
      "description": "Schizophrenia, schizoaffective disorder, schizophreniform disorder",
      "substanceRisks": [
        {
          "substanceId": "*",
          "contraindicationType": "absolute",
          "specificRisks": [
            {
              "risk": "psychotic_episode_induction",
              "severity": "high"
            },
            {
              "risk": "exacerbation_of_symptoms",
              "severity": "high"
            },
            {
              "risk": "prolonged_psychotic_reactions",
              "severity": "high"
            }
          ],
          "requiredPrecautions": [
            "Absolute avoidance recommended",
            "If use occurs, immediate medical attention"
          ],
          "citations": ["aday_2021", "ghaznavi_2025", "white_2024", "bremler_2023", "lowe_2022"],
          "evidenceQuality": "moderate"
        }
      ],
      "familyHistory": {
        "relevant": true,
        "contraindicationType": "absolute",
        "riskMultiplier": "significantly_elevated"
      }
    },
    {
      "id": "cond_bipolar_001",
      "name": "Bipolar Disorder",
      "category": "psychiatric",
      "icd10": "F31",
      "substanceRisks": [
        {
          "substanceId": "*",
          "contraindicationType": "absolute",
          "specificRisks": [
            {
              "risk": "manic_episode_induction",
              "severity": "high"
            },
            {
              "risk": "mood_destabilization",
              "severity": "high"
            }
          ],
          "requiredPrecautions": [
            "Careful screening",
            "Absolute contraindication for active/unstable bipolar",
            "Extreme caution even if stable"
          ],
          "citations": ["aday_2021", "ghaznavi_2025", "white_2024", "bremler_2023"],
          "evidenceQuality": "moderate"
        }
      ],
      "familyHistory": {
        "relevant": true,
        "contraindicationType": "relative",
        "riskMultiplier": "elevated"
      }
    },
    {
      "id": "cond_anxiety_mood_disorders_001",
      "name": "Anxiety and Mood Disorders",
      "category": "psychiatric",
      "icd10": "F30-F48",
      "description": "Major depression, generalized anxiety disorder, panic disorder",
      "substanceRisks": [
        {
          "substanceId": "*",
          "contraindicationType": "relative",
          "riskLevel": "moderate_to_high",
          "specificRisks": {
            "symptomExacerbation": {
              "anxiety": "Can worsen existing anxiety symptoms",
              "depression": "May trigger or worsen depressive episodes"
            }
          },
          "requiredPrecautions": [
            "Thorough assessment",
            "Symptom stability required",
            "Enhanced support during experience",
            "Careful integration planning"
          ],
          "citations": ["ona_2018"],
          "evidenceQuality": "low"
        }
      ]
    },
    {
      "id": "cond_cardiovascular_001",
      "name": "Cardiovascular Conditions",
      "category": "physiological",
      "icd10": "I00-I99",
      "description": "Heart disease, hypertension, arrhythmias",
      "substanceRisks": [
        {
          "substanceId": "2cb_001",
          "contraindicationType": "absolute_if_uncontrolled",
          "riskLevel": "high",
          "mechanism": "Increases heart rate, blood pressure, body temperature",
          "specificRisks": [
            "hypertensive_crisis",
            "arrhythmia",
            "cardiac_events"
          ],
          "citations": ["aday_2020", "fonzo_2025"],
          "evidenceQuality": "low_extrapolated"
        },
        {
          "substanceId": "2ci_001",
          "contraindicationType": "absolute",
          "riskLevel": "critical",
          "documentedEvents": [
            "tachycardia",
            "hypertension",
            "cardiac_arrest"
          ],
          "citations": ["baumeister_2015"],
          "evidenceQuality": "moderate"
        }
      ]
    },
    {
      "id": "cond_trauma_history_001",
      "name": "Unprocessed Trauma History",
      "category": "psychiatric",
      "subcategory": "trauma",
      "description": "History of traumatic experiences, especially if unresolved",
      "severity": "moderate_to_high",
      "substanceRisks": [
        {
          "substanceId": "*",
          "mechanism": "Trauma reactivation during psychedelic state",
          "riskLevel": "moderate",
          "specificRisks": [
            "trauma_reexperiencing",
            "emotional_distress",
            "destabilization"
          ],
          "requiredPrecautions": [
            "Trauma-informed preparation",
            "Specialized integration support",
            "Safety planning",
            "Therapeutic support availability"
          ],
          "citations": ["ona_2018", "breeksema_2022"],
          "evidenceQuality": "low_extrapolated"
        }
      ],
      "contraindicationType": "relative",
      "requiresSpecializedSupport": true
    }
  ],

  "adverseEvents": [
    {
      "id": "ae_anxiety_acute_001",
      "name": "Acute Anxiety",
      "category": "psychological",
      "timeframe": "acute",
      "severity": "mild_to_moderate",
      "description": "Anxiety experienced during or shortly after administration",
      "substanceOccurrence": [
        {
          "substanceId": "2cb_001",
          "prevalence": {
            "note": "Specific prevalence data not available; extrapolated from general psychedelic use",
            "generalPsychedelicRate": "15-100%",
            "context": "Wide variation across studies and doses"
          },
          "management": {
            "primary": "reassurance",
            "effectiveness": "Usually sufficient",
            "escalation": "Benzodiazepines if reassurance insufficient"
          },
          "citations": ["baumeister_2015", "hirschfeld_2021"],
          "evidenceQuality": "very_low"
        }
      ],
      "riskFactors": [
        "rf_anxiety_history_001",
        "rf_unprepared_001",
        "rf_high_dose_001",
        "rf_neuroticism_001"
      ],
      "interventions": [
        "verbal_reassurance",
        "breathing_exercises",
        "grounding_techniques",
        "environmental_adjustment",
        "benzodiazepines_if_severe"
      ]
    },
    {
      "id": "ae_paranoia_001",
      "name": "Paranoid Ideation",
      "category": "psychological",
      "timeframe": "acute",
      "severity": "moderate_to_severe",
      "description": "Paranoid thoughts and suspiciousness during experience",
      "substanceOccurrence": [
        {
          "substanceId": "2ci_001",
          "prevalence": "documented",
          "associatedWith": ["aggression", "confusion"],
          "riskLevel": "moderate_to_high",
          "citations": ["baumeister_2015"],
          "evidenceQuality": "low"
        }
      ],
      "management": {
        "nonPharmacological": [
          "calm_environment",
          "reassurance",
          "avoid_confrontation"
        ],
        "pharmacological": [
          "benzodiazepines_first_line",
          "antipsychotics_if_severe"
        ]
      }
    },
    {
      "id": "ae_cardiovascular_001",
      "name": "Cardiovascular Effects",
      "category": "physiological",
      "subcategory": "cardiovascular",
      "timeframe": "acute",
      "severity": "moderate_to_severe",
      "description": "Increased heart rate, blood pressure, risk of cardiac events",
      "substanceOccurrence": [
        {
          "substanceId": "2ci_001",
          "symptoms": [
            "tachycardia",
            "hypertension",
            "cardiac_arrest",
            "respiratory_arrest"
          ],
          "severity": "severe_to_critical",
          "prevalence": "documented in emergency presentations",
          "citations": ["baumeister_2015"],
          "evidenceQuality": "moderate"
        },
        {
          "substanceId": "2cb_001",
          "symptoms": [
            "increased_heart_rate",
            "increased_blood_pressure"
          ],
          "severity": "mild_to_moderate",
          "prevalence": "presumed common based on class effects",
          "citations": ["aday_2020", "fonzo_2025"],
          "evidenceQuality": "very_low_extrapolated"
        }
      ],
      "monitoring": [
        "vital_signs_monitoring",
        "ECG_if_symptoms_present",
        "emergency_medical_services_if_severe"
      ],
      "treatment": [
        "supportive_care",
        "beta_blockers_if_indicated",
        "emergency_intervention_for_cardiac_events"
      ]
    },
    {
      "id": "ae_renal_failure_001",
      "name": "Renal Failure",
      "category": "physiological",
      "subcategory": "renal",
      "timeframe": "acute_to_subacute",
      "severity": "critical",
      "description": "Acute kidney injury or renal failure",
      "substanceOccurrence": [
        {
          "substanceId": "2ci_001",
          "prevalence": "rare but documented",
          "context": "Emergency presentations",
          "severity": "life_threatening",
          "citations": ["baumeister_2015"],
          "evidenceQuality": "low"
        }
      ],
      "treatment": [
        "immediate_medical_attention",
        "supportive_care",
        "dialysis_if_indicated",
        "hospitalization_required"
      ]
    },
    {
      "id": "ae_seizures_001",
      "name": "Seizures",
      "category": "physiological",
      "subcategory": "neurological",
      "timeframe": "acute",
      "severity": "severe_to_critical",
      "description": "Seizure activity",
      "substanceOccurrence": [
        {
          "substanceId": "2ci_001",
          "prevalence": "documented in emergency presentations",
          "severity": "severe",
          "citations": ["baumeister_2015"],
          "evidenceQuality": "low"
        },
        {
          "substanceId": "2cb_001",
          "route": "insufflation",
          "prevalence": "documented as risk",
          "mechanism": "Direct neurological impact",
          "severity": "severe",
          "citations": ["hirschfeld_2021"],
          "evidenceQuality": "moderate"
        },
        {
          "substanceId": "*",
          "interaction": "lithium",
          "prevalence": "significantly increased risk",
          "severity": "critical",
          "citations": ["nayak_2021"],
          "evidenceQuality": "strong"
        }
      ],
      "treatment": [
        "immediate_medical_attention",
        "benzodiazepines",
        "airway_protection",
        "emergency_services"
      ]
    },
    {
      "id": "ae_cerebral_edema_001",
      "name": "Cerebral Edema",
      "category": "physiological",
      "subcategory": "neurological",
      "timeframe": "acute",
      "severity": "critical",
      "description": "Brain swelling",
      "substanceOccurrence": [
        {
          "substanceId": "2cb_001",
          "route": "insufflation",
          "prevalence": "documented risk",
          "severity": "life_threatening",
          "citations": ["hirschfeld_2021"],
          "evidenceQuality": "moderate"
        }
      ],
      "treatment": [
        "immediate_emergency_medical_services",
        "hospital_admission",
        "intensive_care",
        "neurosurgical_consultation"
      ]
    },
    {
      "id": "ae_cerebral_vasculopathy_001",
      "name": "Cerebral Vasculopathy",
      "category": "physiological",
      "subcategory": "neurological",
      "timeframe": "acute",
      "severity": "critical",
      "description": "Blood vessel abnormalities in the brain",
      "substanceOccurrence": [
        {
          "substanceId": "2cb_001",
          "route": "insufflation",
          "prevalence": "documented risk",
          "severity": "severe_to_critical",
          "citations": ["hirschfeld_2021"],
          "evidenceQuality": "moderate"
        }
      ],
      "treatment": [
        "immediate_medical_attention",
        "neurological_assessment",
        "imaging",
        "specialist_consultation"
      ]
    },
    {
      "id": "ae_serotonin_syndrome_001",
      "name": "Serotonin Syndrome",
      "category": "physiological",
      "subcategory": "neurotoxicity",
      "timeframe": "acute",
      "severity": "severe_to_critical",
      "description": "Potentially life-threatening condition from excessive serotonin",
      "symptoms": {
        "autonomic": [
          "hyperthermia",
          "tachycardia",
          "hypertension",
          "diaphoresis",
          "mydriasis"
        ],
        "neuromuscular": [
          "muscle_rigidity",
          "tremor",
          "hyperreflexia",
          "clonus"
        ],
        "cognitive": [
          "agitation",
          "confusion",
          "delirium"
        ],
        "severe": [
          "seizures",
          "rhabdomyolysis",
          "disseminated_intravascular_coagulation",
          "death"
        ]
      },
      "substanceOccurrence": [
        {
          "substanceId": "2cb_001",
          "triggeringCombinations": [
            {
              "combination": "2C-B + SSRIs",
              "severity": "high",
              "mechanism": "Excessive serotonergic activity"
            },
            {
              "combination": "2C-B + MAOIs",
              "severity": "critical",
              "mechanism": "Severe serotonin accumulation"
            },
            {
              "combination": "2C-B + triptans",
              "severity": "high",
              "mechanism": "Additive serotonergic effects"
            }
          ],
          "route": "any, especially insufflation",
          "riskLevel": "critical",
          "citations": ["hirschfeld_2021"],
          "evidenceQuality": "moderate"
        }
      ],
      "onset": "Rapid (minutes to hours after exposure)",
      "duration": "Variable; requires medical management",
      "treatment": {
        "primary": "Discontinuation of serotonergic agents",
        "supportive": [
          "Benzodiazepines",
          "Cooling measures",
          "IV fluids",
          "Vital sign monitoring"
        ],
        "severe": [
          "ICU admission",
          "Serotonin antagonists (cyproheptadine)",
          "Intubation if needed"
        ]
      },
      "prevention": {
        "screening": "Comprehensive medication review essential",
        "education": "Clear warnings about dangerous combinations",
        "avoidance": "Absolute contraindication for certain combinations"
      },
      "mortality": "Can be fatal without treatment"
    },
    {
      "id": "ae_hppd_001",
      "name": "Hallucinogen Persisting Perception Disorder (HPPD)",
      "category": "perceptual",
      "timeframe": "long_term",
      "severity": "variable",
      "description": "Persistent perceptual disturbances long after drug effects have worn off",
      "substanceOccurrence": [
        {
          "substanceId": "25i_nbome_001",
          "prevalence": {
            "regularUse": {
              "value": 67,
              "unit": "percent",
              "context": "Chronic or prolonged effects with regular use"
            },
            "singleUse": {
              "value": 20,
              "unit": "percent",
              "context": "Risk even from single use"
            }
          },
          "riskPattern": "Higher risk with regular use; elevated risk compared to classical psychedelics",
          "citations": ["retrospective_analysis_nd"],
          "evidenceQuality": "moderate"
        },
        {
          "substanceId": "2cb_001",
          "prevalence": {
            "note": "Limited specific data; presumed similar to classical psychedelics but possibly lower",
            "generalEstimate": "Rare in controlled settings"
          },
          "evidenceQuality": "very_low"
        }
      ],
      "symptoms": [
        "visual_snow",
        "geometric_patterns",
        "trailing",
        "intensified_colors",
        "palinopsia",
        "afterimages"
      ],
      "riskFactors": [
        {
          "factor": "rf_frequent_use_001",
          "evidence": "strong",
          "specificTo": "25I-NBOMe"
        },
        {
          "factor": "rf_high_dose_001",
          "evidence": "moderate"
        },
        {
          "factor": "rf_polydrug_use_001",
          "evidence": "moderate"
        }
      ],
      "treatment": [
        "reassurance",
        "benzodiazepines_anecdotal",
        "lamotrigine_case_reports",
        "cognitive_behavioral_therapy"
      ]
    },
    {
      "id": "ae_prolonged_psychosis_001",
      "name": "Prolonged Psychotic Reactions",
      "category": "psychological",
      "timeframe": "extended",
      "severity": "severe",
      "description": "Psychotic symptoms persisting beyond acute drug effects",
      "substanceOccurrence": [
        {
          "substanceId": "*",
          "prevalence": "Rare but documented",
          "duration": "Days to weeks or longer",
          "riskFactors": [
            "personal_history_psychosis",
            "family_history_psychosis",
            "high_doses",
            "unsupported_settings"
          ],
          "citations": ["baumeister_2015", "barnett_2021", "sabe_2024"],
          "evidenceQuality": "low"
        }
      ],
      "treatment": [
        "psychiatric_evaluation",
        "antipsychotic_medication",
        "supportive_therapy",
        "hospitalization_if_severe"
      ]
    },
    {
      "id": "ae_confusion_001",
      "name": "Confusion and Disorientation",
      "category": "psychological",
      "timeframe": "acute",
      "severity": "mild_to_moderate",
      "description": "Cognitive impairment, disorientation",
      "substanceOccurrence": [
        {
          "substanceId": "2ci_001",
          "prevalence": "Common in adverse presentations",
          "associatedWith": ["paranoia", "aggression"],
          "citations": ["baumeister_2015"],
          "evidenceQuality": "low"
        }
      ],
      "management": [
        "calm_environment",
        "orientation_cues",
        "reassurance",
        "monitoring"
      ]
    },
    {
      "id": "ae_aggression_001",
      "name": "Aggression",
      "category": "behavioral",
      "timeframe": "acute",
      "severity": "moderate_to_severe",
      "description": "Aggressive or violent behavior",
      "substanceOccurrence": [
        {
          "substanceId": "2ci_001",
          "prevalence": "Documented",
          "associatedWith": ["paranoia", "confusion"],
          "safetyImplications": "Risk to self and others",
          "citations": ["baumeister_2015"],
          "evidenceQuality": "low"
        }
      ],
      "management": [
        "maintain_safe_distance",
        "calm_approach",
        "de_escalation_techniques",
        "benzodiazepines",
        "physical_restraint_if_necessary",
        "emergency_services_if_severe"
      ]
    }
  ],

  "therapeuticAlliance": [
    {
      "id": "alliance_quality_001",
      "name": "Therapeutic Alliance Quality",
      "category": "relational",
      "description": "Quality of relationship between therapist/facilitator and participant",
      "importance": "critical",
      "impact": "Strong predictor of outcomes",
      "applicabilityTo2CX": "Limited therapeutic use means less established protocols",
      "components": [
        {
          "component": "safety",
          "description": "Participant feels physically and emotionally safe"
        },
        {
          "component": "trust",
          "description": "Confidence in facilitator's competence and intentions"
        },
        {
          "component": "collaboration",
          "description": "Shared decision-making and goals"
        }
      ],
      "positiveCharacteristics": [
        "open",
        "empathetic",
        "non-judgmental",
        "knowledgeable_about_substance"
      ],
      "negativeCharacteristics": [
        "rigid",
        "critical",
        "distant",
        "lacking_substance_knowledge"
      ],
      "specificTo2CX": "Given limited research, facilitators must acknowledge uncertainty while maintaining supportive presence"
    }
  ],

  "boundaryViolations": [
    {
      "id": "boundary_sexual_001",
      "name": "Sexual Misconduct",
      "category": "ethical_violation",
      "severity": "critical",
      "description": "Sexual touching, contact, or exploitation during psychedelic therapy",
      "riskFactors": [
        "Heightened suggestibility during psychedelic state",
        "Vulnerability and trust",
        "Power imbalances",
        "Lack of clear ethical guidelines",
        "Inadequate practitioner training",
        "Absence of oversight"
      ],
      "prevention": [
        "Clear ethical boundaries",
        "Training on power dynamics",
        "Same-gender facilitator options",
        "Multiple facilitators present",
        "Reporting mechanisms"
      ]
    },
    {
      "id": "boundary_epistemic_001",
      "name": "Epistemic Harm/Belief Imposition",
      "category": "ethical_violation",
      "severity": "moderate_to_high",
      "description": "Imposing beliefs or interpretations onto participants",
      "specificTo2CX": "Limited research means facilitators may impose personal theories or experiences inappropriately",
      "mechanisms": [
        "Interpreting experiences for client",
        "Marginalizing client's perspective",
        "Pressure to adopt facilitator's worldview"
      ],
      "consequences": [
        "False insights becoming solidified beliefs",
        "Undermined autonomy",
        "Psychological distress"
      ],
      "prevention": [
        "Non-directive support",
        "Respecting client's interpretive framework",
        "Not imposing meaning",
        "Acknowledging uncertainty about substance"
      ]
    }
  ],

  "preparationPractices": [
    {
      "id": "prep_screening_001",
      "name": "Comprehensive Screening",
      "category": "assessment",
      "timing": "pre_session",
      "specificTo2CX": "Critical given limited safety data and high variability in illicit market",
      "components": [
        {
          "area": "psychiatric_history",
          "focus": [
            "Personal history of mental illness",
            "Family history of psychosis/bipolar",
            "Current symptoms",
            "Treatment history"
          ]
        },
        {
          "area": "medical_history",
          "focus": [
            "Cardiovascular conditions",
            "Seizure history",
            "Neurological conditions",
            "Medication review - especially serotonergic drugs"
          ]
        },
        {
          "area": "substance_use",
          "focus": [
            "Current substance use patterns",
            "History of polydrug use",
            "Previous experiences with 2C-X or similar substances",
            "Understanding of substance identity and purity"
          ]
        }
      ],
      "exclusionCriteria": [
        "Active psychosis",
        "Active mania",
        "Unstable cardiovascular disease",
        "Current use of SSRIs/MAOIs/triptans",
        "Lithium use",
        "Pregnancy",
        "Severe liver/kidney impairment"
      ],
      "relativeContraindications": [
        "Family history of psychosis",
        "Anxiety or mood disorders",
        "Trauma history",
        "Controlled cardiovascular conditions"
      ],
      "effectiveness": "high",
      "evidenceQuality": "extrapolated_from_other_psychedelics"
    },
    {
      "id": "prep_substance_verification_001",
      "name": "Substance Testing and Verification",
      "category": "harm_reduction",
      "timing": "pre_session",
      "specificTo2CX": "Critical due to high risk of adulteration and misrepresentation",
      "importance": "critical",
      "rationale": "Illicit market 2C substances often misrepresented or adulterated with dangerous compounds like NBOMes",
      "methods": [
        {
          "method": "reagent_testing",
          "description": "Use of chemical reagents to identify substance class",
          "limitations": "Cannot determine purity or exact dosage",
          "recommendation": "Minimum requirement"
        },
        {
          "method": "laboratory_analysis",
          "description": "Professional testing for exact composition and purity",
          "advantages": "Most reliable method",
          "recommendation": "Ideal when available"
        },
        {
          "method": "test_dose",
          "description": "Taking small amount to assess effects before full dose",
          "recommendation": "Strongly advised",
          "citations": ["baxter_2024"]
        }
      ],
      "redFlags": [
        "Substance sold as something else (e.g., 'LSD' or 'MDMA')",
        "Unknown source",
        "Unusual appearance or smell",
        "Bitter taste (may indicate NBOMe)"
      ]
    },
    {
      "id": "prep_psychoeducation_001",
      "name": "Psychoeducation",
      "category": "education",
      "timing": "pre_session",
      "specificTo2CX": "Must acknowledge limited research and elevated uncertainty",
      "content": [
        {
          "topic": "substance_effects",
          "details": [
            "Limited research available",
            "Expected duration (6-8 hours)",
            "Described as 'lighter' than some psychedelics but still potent",
            "Individual variation high",
            "Risk of misidentified substances"
          ]
        },
        {
          "topic": "risks",
          "details": [
            "Cardiovascular effects",
            "Risk of serotonin syndrome with certain medications",
            "Severe risks from insufflation",
            "Risk from polydrug use, especially MDMA",
            "Psychological risks",
            "Unknown long-term effects"
          ]
        },
        {
          "topic": "harm_reduction",
          "details": [
            "Importance of substance testing",
            "Starting with low doses",
            "Oral administration only",
            "Avoiding drug combinations",
            "Importance of set and setting",
            "Having support person present"
          ]
        }
      ],
      "format": ["Verbal discussion", "Written materials"],
      "effectiveness": "moderate_to_high",
      "evidenceQuality": "extrapolated"
    },
    {
      "id": "prep_route_education_001",
      "name": "Route of Administration Education",
      "category": "education",
      "timing": "pre_session",
      "specificTo2CX": true,
      "importance": "critical",
      "focus": "Strong warnings against insufflation",
      "content": [
        "Oral administration is the only relatively safe route",
        "Insufflation associated with severe neurological complications",
        "Risk of cerebral edema, seizures, and cerebral vasculopathy from insufflation",
        "No safe benefit from alternative routes"
      ],
      "effectiveness": "high_for_behavior_change",
      "citations": ["hirschfeld_2021"]
    }
  ],

  "integrationPractices": [
    {
      "id": "int_therapy_001",
      "name": "Integration Therapy Sessions",
      "category": "professional_support",
      "timing": "post_session",
      "applicabilityTo2CX": "Important but limited therapist expertise available",
      "structure": {
        "initial": {
          "timing": "1-2 days post-session",
          "purpose": "Process immediate experience",
          "duration": "60-90 minutes"
        },
        "ongoing": {
          "frequency": "Weekly to bi-weekly as needed",
          "duration": "Variable based on individual needs",
          "purpose": "Translate insights into behavior change, address difficulties"
        }
      },
      "considerations": [
        "Therapist may have limited familiarity with 2C-X",
        "Focus on general psychedelic integration principles",
        "Emphasize processing unusual or unexpected effects"
      ],
      "effectiveness": "presumed_high",
      "evidenceQuality": "extrapolated"
    },
    {
      "id": "int_peer_support_001",
      "name": "Peer Support and Community",
      "category": "community",
      "timing": "post_session_ongoing",
      "applicabilityTo2CX": "May be primary source of support given limited professional resources",
      "formats": [
        {
          "format": "online_forums",
          "benefits": ["Accessible", "Anonymous option", "Shared experiences"],
          "risks": ["Misinformation", "Lack of professional oversight"]
        },
        {
          "format": "integration_circles",
          "benefits": ["Community support", "Shared learning", "Reduced isolation"],
          "risks": ["Variable facilitator quality", "Potential for groupthink"]
        }
      ],
      "bestPractices": [
        "Seek communities with harm reduction focus",
        "Be cautious of extreme claims",
        "Supplement with professional support when possible"
      ],
      "effectiveness": "moderate",
      "evidenceQuality": "low"
    },
    {
      "id": "int_creative_001",
      "name": "Creative Expression",
      "category": "self_practice",
      "timing": "post_session_ongoing",
      "modalities": [
        {
          "modality": "journaling",
          "frequency": "Daily recommended initially",
          "benefits": ["Process experience", "Track insights", "Identify patterns"]
        },
        {
          "modality": "art",
          "types": ["Drawing", "Painting"],
          "benefits": ["Non-verbal processing", "Expression of ineffable experiences"]
        }
      ],
      "effectiveness": "moderate",
      "evidenceQuality": "extrapolated"
    }
  ],

  "groupDynamicsFactors": [
    {
      "id": "group_common_couse_001",
      "name": "Common Co-Use with MDMA",
      "category": "behavioral",
      "description": "Frequent combination of 2C-B with MDMA in group settings",
      "specificTo2CX": true,
      "prevalence": "Very common",
      "context": "Often used together at events, parties, or in social settings",
      "risks": [
        "Unpredictable interactions",
        "Increased physiological burden",
        "Enhanced serotonergic effects",
        "Difficulty attributing effects to specific substance",
        "Group pressure to combine substances"
      ],
      "citations": ["caudevilla_2012"],
      "harmReduction": [
        "Education about interaction risks",
        "Encouraging single-substance use",
        "If combining, start with lower doses of both",
        "Increased monitoring",
        "Peer education"
      ]
    },
    {
      "id": "group_suggestibility_001",
      "name": "Collective Suggestibility",
      "category": "psychological",
      "description": "Heightened suggestibility in group settings during psychedelic states",
      "risks": [
        "Adoption of harmful beliefs",
        "Group pressure for risky behavior (e.g., combining drugs, higher doses)",
        "Loss of individual perspective"
      ],
      "prevention": [
        "Individual preparation and intention-setting",
        "Clear group agreements beforehand",
        "Trained facilitators",
        "Emphasis on individual autonomy"
      ]
    }
  ],

  "culturalSpiritualFactors": [
    {
      "id": "cultural_synthetic_origin_001",
      "name": "Synthetic Origin and Cultural Context",
      "category": "cultural",
      "description": "2C-X compounds are synthetic with no traditional cultural use",
      "specificTo2CX": true,
      "implications": [
        "No established cultural frameworks for interpretation",
        "No traditional protocols or rituals",
        "Limited collective wisdom about use",
        "Western recreational/experimental context predominates"
      ],
      "considerations": [
        "Users must construct their own meaning-making frameworks",
        "Increased importance of individual preparation",
        "Risk of cultural appropriation if borrowing from other traditions",
        "Western medical/scientific framing may be most appropriate"
      ]
    },
    {
      "id": "cultural_rave_festival_context_001",
      "name": "Rave and Festival Culture Context",
      "category": "cultural",
      "description": "Common use in electronic music and festival settings",
      "specificTo2CX": true,
      "culturalContext": "Primarily associated with recreational use in party/festival settings",
      "risks": [
        "Emphasis on hedonistic use over intentional exploration",
        "Environmental stressors (heat, noise, crowds)",
        "Normalization of polydrug use",
        "Lack of preparation and integration",
        "Risk-taking behaviors"
      ],
      "benefits": [
        "Community and shared experience",
        "Peer knowledge sharing",
        "Some harm reduction infrastructure at events"
      ],
      "recommendations": [
        "Apply intentional use principles even in recreational settings",
        "Utilize harm reduction services at events",
        "Plan for safer use strategies",
        "Consider therapeutic use models even outside clinical settings"
      ]
    }
  ],

  "legalSocioeconomicFactors": [
    {
      "id": "legal_prohibition_001",
      "name": "Prohibition and Illegal Status",
      "category": "legal",
      "description": "Harms arising from criminalization of 2C-X compounds",
      "specificTo2CX": "Scheduled as illegal in most jurisdictions",
      "impacts": [
        {
          "impact": "lack_of_quality_control",
          "severity": "critical",
          "description": "No regulation leads to variable purity and dangerous adulterants",
          "specificTo2CX": "High risk of NBOMe adulteration, inconsistent dosing within batches",
          "consequences": ["Unpredictable effects", "Toxicity", "Overdose", "Severe adverse reactions"]
        },
        {
          "impact": "unsafe_acquisition",
          "severity": "moderate_to_high",
          "description": "Exposure to criminal markets"
        },
        {
          "impact": "reluctance_to_seek_help",
          "severity": "high",
          "description": "Fear of legal repercussions prevents help-seeking",
          "consequences": ["Adverse events not treated", "Poor outcomes"]
        },
        {
          "impact": "research_barriers",
          "severity": "critical",
          "description": "Scheduled status severely limits research",
          "specificTo2CX": "Virtually no clinical research, extremely limited safety data",
          "consequences": ["Minimal evidence base", "No established protocols", "Users rely on anecdotal information"]
        }
      ]
    },
    {
      "id": "socioeconomic_access_001",
      "name": "Socioeconomic Barriers",
      "category": "socioeconomic",
      "description": "Financial and resource barriers",
      "specificTo2CX": "No legal therapeutic access, only illicit market",
      "barriers": [
        {
          "barrier": "no_therapeutic_access",
          "description": "No legal therapeutic pathways exist",
          "impact": "All use is unregulated and unsupported"
        },
        {
          "barrier": "quality_testing_costs",
          "description": "Professional substance testing may be expensive or unavailable",
          "impact": "Lower SES individuals less able to verify substance safety"
        }
      ]
    }
  ],

  "contaminationQualityFactors": [
    {
      "id": "contam_nbome_adulteration_001",
      "name": "NBOMe Adulteration",
      "category": "contamination",
      "severity": "critical",
      "description": "Presence of dangerous NBOMe compounds sold as 2C-X or other substances",
      "specificTo2CX": true,
      "prevalence": "Common in illicit market",
      "commonScenarios": [
        {
          "scenario": "Sold as LSD",
          "prevalence": "Very common",
          "risks": ["Higher toxicity", "Prolonged effects", "Severe adverse reactions", "Fatalities"]
        },
        {
          "scenario": "Sold as 2C-B or other 2C-X",
          "prevalence": "Common",
          "risks": ["Unexpected potency", "Different effect profile", "Higher HPPD risk"]
        }
      ],
      "identification": [
        "Bitter taste indicates NBOMe (2C-B typically has minimal taste)",
        "Reagent testing can differentiate",
        "NBOMes more likely to cause severe vasoconstriction"
      ],
      "harmReduction": [
        "Reagent testing essential",
        "Test doses",
        "Avoid if bitter taste",
        "Be aware of warning signs"
      ],
      "citations": ["hirschfeld_2021", "malcolm_2022"],
      "evidenceQuality": "strong"
    },
    {
      "id": "contam_dosage_variability_001",
      "name": "Dosage Variability",
      "category": "quality",
      "severity": "high",
      "description": "Inconsistent concentration within same batch",
      "specificTo2CX": "Documented hot spots and cold spots in 2C-X powder/crystal",
      "consequences": [
        "Accidental overdose",
        "Unexpectedly intense effects",
        "Difficulty establishing safe dose",
        "Inconsistent experiences"
      ],
      "mechanism": [
        "Uneven distribution in powder",
        "Variable tablet pressing",
        "Inconsistent synthesis"
      ],
      "harmReduction": [
        "Volumetric dosing for powder",
        "Thorough mixing if dividing doses",
        "Starting with low doses",
        "Not assuming consistency across purchases"
      ],
      "citations": ["hirschfeld_2021", "bremler_2023"],
      "evidenceQuality": "moderate"
    },
    {
      "id": "contam_misrepresentation_001",
      "name": "Substance Misrepresentation",
      "category": "sourcing",
      "severity": "high",
      "description": "2C-X sold as other substances or vice versa",
      "commonPatterns": [
        {
          "soldAs": "LSD",
          "actualSubstance": "2C-X or NBOMe",
          "risks": ["Unexpected duration", "Different safety profile", "Wrong dose calculation"]
        },
        {
          "soldAs": "MDMA",
          "actualSubstance": "2C-X",
          "risks": ["Different effects", "Wrong expectations", "Inappropriate setting"]
        }
      ],
      "prevention": [
        "Substance testing before use",
        "Reliable sources",
        "Knowledge of substance characteristics",
        "Test doses"
      ],
      "citations": ["petranker_2022", "hirschfeld_2021"],
      "evidenceQuality": "strong"
    },
    {
      "id": "contam_powder_crystal_risks_001",
      "name": "Powder/Crystal Form Risks",
      "category": "quality",
      "severity": "high",
      "description": "Risks specific to powder and crystal formulations",
      "specificTo2CX": "Commonly sold in these forms",
      "risks": [
        "Difficult to measure accurate doses",
        "Easy to overdose without precision scale",
        "Variation within batch",
        "Unknown purity",
        "Temptation to insufflate (dangerous)"
      ],
      "harmReduction": [
        "Use milligram scale (0.001g accuracy)",
        "Volumetric dosing",
        "Never eyeball doses",
        "Oral administration only",
        "Start very low with unknown batches"
      ],
      "citations": ["baumeister_2015", "hirschfeld_2021"],
      "evidenceQuality": "moderate"
    }
  ],

  "emergencyResponseProtocols": [
    {
      "id": "emergency_nonpharm_001",
      "name": "Non-Pharmacological Interventions",
      "category": "crisis_management",
      "priority": "first_line",
      "interventions": [
        {
          "intervention": "continuous_monitoring",
          "description": "Maintain observation and regular verbal contact",
          "importance": "Critical given unpredictable effects and potential for severe complications"
        },
        {
          "intervention": "vital_signs_monitoring",
          "description": "Regular monitoring of heart rate, blood pressure, temperature",
          "specificTo2CX": "Essential given cardiovascular risks",
          "frequency": "Every 15-30 minutes or more frequently if concerning"
        },
        {
          "intervention": "verbal_reassurance",
          "description": "Calm, empathetic reassurance",
          "effectiveness": "Variable - may be insufficient for severe reactions"
        },
        {
          "intervention": "environmental_adjustment",
          "description": "Modify setting to reduce distress",
          "actions": ["Move to quiet area", "Dim lights", "Reduce temperature if hyperthermic"]
        },
        {
          "intervention": "physical_cooling",
          "description": "Active cooling measures if hyperthermia present",
          "specificTo2CX": "Important given risk of dangerous hyperthermia",
          "methods": ["Cool room", "Cool cloths", "Fans"]
        }
      ],
      "limitations": "May be insufficient for severe physiological reactions",
      "escalationCriteria": [
        "Persistent tachycardia or hypertension",
        "Hyperthermia",
        "Seizure activity",
        "Severe agitation or aggression",
        "Altered consciousness",
        "Chest pain"
      ]
    },
    {
      "id": "emergency_pharm_001",
      "name": "Pharmacological Interventions",
      "category": "crisis_management",
      "priority": "second_line",
      "specificTo2CX": "More likely to be needed than with classical psychedelics",
      "medications": [
        {
          "medication": "benzodiazepines",
          "indication": "Anxiety, agitation, seizures",
          "dosing": {
            "typical": {"value": 10, "unit": "mg", "route": "oral", "medication": "diazepam"},
            "severe": {"min": 15, "max": 30, "unit": "mg"}
          },
          "effectiveness": "Generally effective for psychological distress",
          "availability": "Should be immediately available"
        },
        {
          "medication": "antipsychotics",
          "indication": "Severe psychosis, aggression unresponsive to benzodiazepines",
          "cautions": [
            "Use with extreme caution",
            "May worsen some symptoms",
            "Should be administered by medical professionals only"
          ],
          "preference": "Atypical antipsychotics (olanzapine, risperidone) over haloperidol"
        }
      ],
      "medicalSupervision": "Required for any pharmacological intervention"
    },
    {
      "id": "emergency_medical_001",
      "name": "Emergency Medical Services",
      "category": "crisis_management",
      "priority": "escalation",
      "specificTo2CX": "Lower threshold for calling EMS given severe complications documented",
      "whenToCall": [
        "Cardiovascular symptoms (chest pain, severe tachycardia/hypertension)",
        "Seizure activity",
        "Suspected serotonin syndrome",
        "Severe hyperthermia",
        "Altered consciousness",
        "Suspected renal or hepatic complications",
        "Severe agitation/aggression not responding to benzodiazepines",
        "Any life-threatening symptoms"
      ],
      "preparedness": [
        "Emergency numbers readily available",
        "Knowledge of nearest emergency facility",
        "Basic information about substance taken (if known)",
        "Vital signs if available"
      ],
      "informationForEMS": [
        "Substance believed taken",
        "Time of ingestion",
        "Route of administration",
        "Dose if known",
        "Other substances consumed",
        "Vital signs",
        "Duration of symptoms",
        "Medical history including medications"
      ]
    },
    {
      "id": "emergency_serotonin_syndrome_protocol_001",
      "name": "Serotonin Syndrome Protocol",
      "category": "specific_emergency",
      "specificTo2CX": "High risk given serotonergic activity",
      "recognition": {
        "symptoms": [
          "Hyperthermia",
          "Agitation/restlessness",
          "Muscle rigidity/clonus",
          "Hyperreflexia",
          "Tachycardia",
          "Hypertension",
          "Dilated pupils",
          "Diaphoresis"
        ],
        "severity": "Life-threatening emergency"
      },
      "immediateActions": [
        "Call emergency services immediately",
        "Discontinue any serotonergic substances",
        "Cooling measures for hyperthermia",
        "Benzodiazepines for agitation/seizures",
        "Monitor vital signs",
        "Prepare for rapid transport"
      ],
      "hospitalTreatment": [
        "Aggressive cooling",
        "IV fluids",
        "Cyproheptadine (serotonin antagonist)",
        "ICU admission likely",
        "Management of complications"
      ]
    },
    {
      "id": "emergency_neurological_complications_001",
      "name": "Neurological Emergency Protocol",
      "category": "specific_emergency",
      "specificTo2CX": "Risk of cerebral edema, vasculopathy, seizures especially with insufflation",
      "symptoms": [
        "Severe headache",
        "Seizures",
        "Altered consciousness",
        "Focal neurological signs",
        "Severe confusion"
      ],
      "immediateActions": [
        "Call emergency services immediately",
        "Protect airway if consciousness altered",
        "Position for seizure safety if needed",
        "Do not give anything by mouth",
        "Monitor vital signs",
        "Prepare for rapid transport"
      ],
      "hospitalCare": [
        "Neuroimaging (CT/MRI)",
        "Neurological consultation",
        "Management of cerebral edema if present",
        "ICU admission likely"
      ]
    }
  ],

  "assessmentTools": [
    {
      "id": "tool_general_psychedelic_001",
      "name": "General Psychedelic Assessment Tools",
      "applicabilityTo2CX": "No specific tools exist; general psychedelic tools may be used with caution",
      "note": "Lack of 2C-X specific validation",
      "examples": [
        {
          "tool": "Swiss Psychedelic Side Effects Inventory",
          "limitation": "Not validated for 2C-X specifically"
        },
        {
          "tool": "Challenging Experience Questionnaire",
          "limitation": "Not validated for 2C-X specifically"
        }
      ]
    }
  ],

  "doseResponseCurves": [
    {
      "note": "No formal dose-response data available for 2C-X family",
      "generalPrinciple": "Assume dose-dependent increase in both desired effects and adverse events",
      "specificConsiderations": [
        "Steep dose-response curve possible",
        "Individual variability high",
        "Batch variability significant",
        "No established therapeutic window"
      ]
    }
  ],

  "complexInteractions": [
    {
      "id": "interact_complex_001",
      "factors": [
        {"type": "substance", "id": "2cb_001"},
        {"type": "medication", "class": "SSRI"},
        {"type": "setting", "description": "hot_environment"}
      ],
      "riskMultiplier": "critical",
      "specificOutcome": "Severe serotonin syndrome with hyperthermia",
      "mechanism": [
        "2C-B serotonergic activity",
        "SSRI inhibits serotonin reuptake",
        "Environmental heat increases body temperature",
        "Synergistic serotonergic overload"
      ],
      "prevention": [
        "Absolute avoidance of SSRIs with 2C-X",
        "Cool environment essential",
        "Hydration",
        "Immediate cooling if hyperthermia develops"
      ],
      "evidenceQuality": "moderate"
    },
    {
      "id": "interact_complex_002",
      "factors": [
        {"type": "substance", "id": "2cb_001"},
        {"type": "substance", "name": "MDMA"},
        {"type": "setting", "description": "party/festival"},
        {"type": "risk_factor", "id": "rf_age_youth_001"}
      ],
      "riskMultiplier": "high",
      "specificOutcome": "Unpredictable combination effects, increased physiological burden",
      "mechanism": [
        "Common combination in party settings",
        "Both affect serotonin",
        "Additive cardiovascular effects",
        "Young brain more vulnerable",
        "Environmental stressors"
      ],
      "prevalence": "Very common combination",
      "prevention": [
        "Education about combination risks",
        "Encourage single-substance use",
        "If combining, use lower doses of both",
        "Increased monitoring",
        "Cooler environment"
      ],
      "evidenceQuality": "low"
    },
    {
      "id": "interact_complex_003",
      "factors": [
        {"type": "substance", "id": "2cb_001"},
        {"type": "route", "description": "insufflation"},
        {"type": "risk_factor", "description": "unknown_purity"}
      ],
      "riskMultiplier": "critical",
      "specificOutcome": "Severe neurological complications",
      "mechanism": [
        "Insufflation increases risk of severe neurological reactions",
        "Unknown purity means unknown dose",
        "Possible NBOMe contamination",
        "Direct nasal/sinus tissue damage"
      ],
      "specificRisks": [
        "Cerebral edema",
        "Cerebral vasculopathy",
        "Seizures",
        "Central serotonin syndrome"
      ],
      "prevention": [
        "Never insufflate 2C-X compounds",
        "Oral administration only",
        "Substance testing",
        "Start with low oral doses"
      ],
      "evidenceQuality": "moderate",
      "citations": ["hirschfeld_2021"]
    }
  ],

  "metadata": {
    "documentSource": "Psychedelic Safety Literature Review - 2C-X Section",
    "substanceFamily": "2C-X (phenethylamines)",
    "primarySubstances": ["2C-B", "2C-I", "25I-NBOMe"],
    "researchStatus": "Very limited clinical research",
    "dataQuality": "Low to very low for most parameters",
    "geographicScope": "Global illicit market data",
    "lastLiteratureSearch": "2024",
    "qualityAssessment": "Severely limited by lack of controlled research",
    "knownLimitations": [
      "Extremely limited clinical research",
      "Most data from case reports and user surveys",
      "High variability in illicit market compounds",
      "Frequent misrepresentation and adulteration",
      "No established therapeutic protocols",
      "Limited long-term outcome data",
      "Significant underreporting likely",
      "Much extrapolated from other psychedelics",
      "No diversity data in limited research",
      "Synthesis and chemistry highly variable"
    ],
    "criticalGaps": [
      "No clinical trials",
      "No established safety profiles",
      "No pharmacokinetic studies",
      "Limited toxicology data",
      "No therapeutic dosing guidelines",
      "Minimal understanding of long-term effects",
      "No drug interaction studies",
      "Limited understanding of metabolism"
    ],
    "evidenceBase": "Primarily anecdotal, case reports, and illicit market surveillance",
    "recommendedCaution": "Extreme caution advised due to limited safety data and high market variability"
  }
}